Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

Sponsor
Hui Bu
Study ID
NCT04356222
Phase
PHASE4
Status
Unknown

Conditions

  • Durvalumab
  • Leptomeningeal Metastasis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    Intravenous infusion once every two weeks ,once 10mg/kg.
  • methotrexate — DRUG
    Intrathecal chemotherapy specified dose on specified days

Study Details

The purpose of this study is to observe the clinical efficacy and safety of Durvalumab combined with intrathecal chemotherapy in non-small cell lung cancer with leptomeningeal metastasis

Key Dates

Start date
Jun 30, 2020
Status verified
May 2020
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Leptomeningeal Metastasis
    Durvalumab + Intrathecal chemotherapy

Primary Outcome Measure

overall survival (OS) [ Time Frame: 36 months ]

Central Contacts

Related Studies